Two technical papers produced by Baxa Corporation – “Understanding USP 797” and “Environmental Controls for Sterile Compounding” are now posted for media and professional access on PublicRelationsNewsroom.com. Since the American Society of Health-System Pharmacists (ASHP) released USP 797 in January 2004 and the National Institute for Occupational Safety and Health (NIOSH) published its 2004 alert on the health risks posed to those working with hazardous drugs, there has been a renewed focus on safety within the hospital pharmacy environment. These papers address the various issues under discussion.
Englewood, CO (PRWEB) January 30, 2005 -- With hazardous drug handling
brought to the forefront of public scrutiny in 2004 by the American Society of
Health-System Pharmacists (ASHP) USP 797 and a related National Institute for
Occupational Safety and Health (NIOSH) Alert, Baxa Corporation has published two
related technical papers: “Understanding USP 797” and “Environmental Controls
for Sterile Compounding.” Both papers are now posted on www.PublicRelationsNewsroom.com for both professional and
media access (click either the ASHP USP 797 tab or the compounding tab if
accessing from the home page), according to Greg Baldwin, Chairman and CEO of
Baxa Corporation. Baxa is the US distributor of PhaSeal®, the only closed system
that prevents the workplace contamination threats as delineated in the NIOSH
“Understanding USP 797” is found at http://www.publicrelationsnewsroom.com/_wsn/page4.html. This paper is authored by Baxa Corporation’s Michael Hurst RPh, MBA.
Hurst worked for 18 years at Swedish Medical Center in Seattle, WA, in operational management, including positions as IV Supervisor and Assistant Director of Pharmacy. His implementation of a syringe infusion system in 1984 had national implications. For the next nine years Hurst wrote, spoke, consulted and acted as a reference site for syringe infusion installations across the country.
Moving to industry full time in 1994, Hurst joined Baxa Corporation as Vice President of Infusion Systems. His job duties have included customer support for syringe infusion system installations, new business and product development roles, and professional services support for various Baxa pharmacy and nursing product lines. Hurst is currently consulting with a hospital system in the development of a comprehensive USP 797 compliance template that can be applied in other hospital pharmacies.
“Environmental Controls for Sterile Compounding” is found at http://www.publicrelationsnewsroom.com/_wsn/page6.html.
Baxa Corporation, as previously mentioned, offers the only closed system for safe handling of antineoplastic and other hazardous drugs. This system, PhaSeal®, uses dry connections and a built-in expansion chamber to prevent drug aerosol leakage and subsequent transfer into the work environment. As a closed system, it contains hazardous drugs throughout the entire process of drug transfer, preparation, transport, administration and disposal - eliminating the risks of environmental and occupational exposure. The PhaSeal System is currently in use for handling hazardous drugs in more than 200 leading cancer hospitals in the US. The system is also used in progressive hospitals throughout Europe.
A leading provider of devices and systems for the preparation, handling, packaging, and administration of liquid medications, Baxa Corporation manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Headquartered in Englewood, Colorado, Baxa has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at http://www.baxa.com.
The PhaSeal System is manufactured in Sweden by Carmel Pharma ab of Göteborg, Sweden. Introduced in Europe in 1994, the PhaSeal System is now used in most Swedish hospitals, with its benefits documented by a significant body of scientific research on the health risks associated with the preparation and administration of cytotoxic drugs. The PhaSeal System is protected by a comprehensive patent portfolio in the U.S., European Union and Japan. For more information on Carmel Pharma, please visit http://www.carmelpharma.se.
Additional resources regarding this subject matter:
Understanding CleanRooms: A Q&A Document
Safe Handling of Hazardous Drugs in the Workplace: Expert Perspectives
"What if the Cure is Also a Cause?
The Same Chemo Drugs That Save Some Cancer Patients' Lives Put Health Workers at Risk"
A Major Daily Newspaper Looks at This Issue in Depth: February 15, 2005
Click the following link to view a presentation by Jim Jorgenson "Using a Closed System Device to Reduce Occupational Exposure to Hazardous Drugs." Jorgenson is Director of Pharmacy for the Huntsman Cancer Institute and Associate Dean for Professional Affairs at the University of Utah:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: e-mail protected from spam bots
Maggie Chamberlin Holben, APR, Absolutely Public Relations
303.984.9801, 303.669.3558 Email: e-mail protected from spam bots
# # #
Source : http://www.prweb.com/releases/2005/1/prweb202867.htm